Detalhe da pesquisa
1.
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Haemophilia
; 27(3): e331-e339, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772963
2.
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
N Engl J Med
; 377(9): 819-828, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28691885
3.
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
J Thromb Haemost
; 19(6): 1436-1446, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587824
4.
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
Clin Appl Thromb Hemost
; 26: 1076029620950836, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32866032
5.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Clin Appl Thromb Hemost
; 26: 1076029620946839, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816519
6.
Fibrinogen-modified sodium alginate as a scaffold material for skin tissue engineering.
Biomed Mater
; 13(2): 025007, 2018 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28972200
7.
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
Thromb Res
; 137: 119-125, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26614676
8.
Bioceramics composed of octacalcium phosphate demonstrate enhanced biological behavior.
ACS Appl Mater Interfaces
; 6(19): 16610-20, 2014 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25184694